Sodium-glucose cotransporter 2 (SGLT2) inhibitors, originally conceived as antihyperglycaemic agents, favourably lower the risk of CV events in people living with T2DM albeit with some heterogeneity [18–21] while risk of heart failure (HF) hospitalisations is more consistently reduced by the class regardless of diabetes status [18–25]. Here, SLC5A2 is linked to type 2 diabetes mellitus.